Fairwinds

Participants offered feedback to DOH staff questions related to their medical cannabis testing requirements and then posed questions of their own to officials.

Organization leaders and attendees heard from two prominent legislators on long-running cannabis topics and expected priorities for the 2024 regular legislative session.

A mostly new team at the DOH Medical Cannabis Program solicited feedback on potential revisions to rules on compliant products, testing, labeling, and logos.

A last-minute hearing on a repackaged bill to regulate synthesized cannabinoids revealed shared public health concerns but testimony otherwise remained just as sharply divided.

Testimony on a bill to exempt registered medical cannabis patients from the excise tax on DOH compliant products was supportive and elicited several questions from lawmakers.

Some licensees, WSLCB staff, and prevention advocates encouraged lawmakers to pass request legislation on cannabinoid regulation, while other licensees preferred a competing bill.

A majority of speakers favored legislation to create a cannabis commodity commission, but questions remained about costs, goals, and the inclusiveness with which the bill was drafted.